Strengthening Our Impact with Growth and Expansion of Our Capabilities
At Veristat, we champion innovation through the solutions we provide our clients across clinical trials and on specialized projects, supporting the success of therapies designed to extend, save and enrich lives. Over the years, we have strategically invested in organizations, people and resources to help our clients solve their most complex challenges.
With our bold scientific strategies and a team unafraid of big thinking, we are passionate about helping you get your therapy to market– and keep it there – quickly, safely and cost-effectively.
HISTORY AND TIMELINE OF VERISTAT'S GROWTH
Veristat becomes a registered CDISC solutions provider, integral to our offering to ensure timely and compliant FDA submissions and reviews.
Patrick Flanagan joins as CEO to lead the company’s business strategy, organizational management and financial performance.
Veristat’s acquisition of TCTC brings substantive capabilities and talent in Advanced Therapy solutions, furthering geographic reach into the UK and EU regions.
The acquisition of Certus PV advances Veristat’s commitment to patient safety by adding post-market pharmacovigilance services.
Enhances patient-centricity offering by launching a flexible virtual clinical trial solution.
The acquisition of SFL adds commercialization capabilities, expands our EU footprint and diversifies our client base.
Launches Strategic Resourcing/FSP solutions to build greater flexibility for sponsors.